FierceHealthcare reports today that a recent study conducted by Avalere Health LLC found that for the largest 10 drug companies, premiums are expected to rise up an average of 31 percent next year. It is also speculated that this in term might cause insurers to increase drug co-payments 75 percent (about $7) for generic drugs and a 60% increase (about $40) for brand drugs.
A spokesperson from Humana, an insurer, mentions:
“Prices reflect the experience we've seen over the past three years, and our expectations around what will most interest our members and potential members going forward."
About Us
Health Care Insights - From Policy to Practice is the trusted source for news and commentary from the nation's leading Health Care Events such as Medicaid Drug Rebate Program Summit (MDRP), Medicaid Managed Care Congress (MMCC), FDA/CMS to inform Health Plans and Pharmaceutical Manufacturers on the latest developments on Medicare, Medicaid Managed Care, Government Programs, and Health Insurance Exchanges.
Topics we cover include reform, best business practices, the latest innovations, and novel payment models.
No comments:
Post a Comment